Matthew Kapusta Sells 28,716 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 28,716 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $50.02, for a total value of $1,436,374.32. Following the completion of the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at $25,971,734.54. The trade was a 5.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Trading Down 3.2%

QURE traded down $1.59 during midday trading on Friday, hitting $47.51. The company’s stock had a trading volume of 3,154,443 shares, compared to its average volume of 2,765,936. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The firm has a 50-day moving average price of $27.23 and a two-hundred day moving average price of $22.85. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market cap of $3.00 billion, a P/E ratio of -13.65 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, research analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current year.

Analyst Ratings Changes

QURE has been the subject of several research reports. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research note on Tuesday, May 5th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research report on Wednesday, June 17th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $25.00 to $65.00 in a report on Thursday, June 18th. TD Cowen reissued a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Finally, Chardan Capital upped their price target on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $61.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Torren Management LLC bought a new position in uniQure during the 4th quarter valued at $28,000. IFP Advisors Inc acquired a new stake in shares of uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the 4th quarter valued at about $48,000. CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the third quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.